MENU
IKT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Inhibikase Therapeutics (IKT) Ownership - Who owns Inhibikase Therapeutics?
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (“PDâ€), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases... Show more
Profile
Industry
N/A
Address
3350 Riverwood Parkway SE
Phone
+1 678 392-3419
Employees
14
Web
https://www.inhibikase.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
158.45M
P/E Ratio
N/A
Total Cash
3.24M
Projected Growth
N/A
Total Debt
145.21K
Revenue
N/A
Risk (Beta)
1.23
Dividend Yield
N/A
Total Cash/Share
0.04
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
IKT
Capitalization
158M
P/E Ratio
N/A
Risk (Beta)
1.23
Dividend Yield
N/A
Total Cash
3.24M
Total Cash/Share
0.04
Total Debt
145K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
-530.59K
P/B Ratio
26.46
Cash Flow
N/A
Earnings
-3.12
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
7.46K
Current Ratio
0.85
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-20.04M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-175.81
Shares Held By Institutions
164M
Shares Outstanding - Current
72.7M
Total Liabilities
4.91M
Total Volume MTD
N/A
Value
-1
Gain YTD
-32.615
View a ticker or compare two or three
VS
VS
Show more...
Ad is loading...
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
3350 Riverwood Parkway SE
Phone
+1 678 392-3419
Employees
14
Web
https://www.inhibikase.com